open access

Vol 67, No 5 (2016)
Original papers
Published online: 2016-01-25
Submitted: 2015-09-08
Accepted: 2015-10-20
Get Citation

The effect of sleeve gastrectomy on serum irisin levels in patients with morbid obesity

Mustafa Demirpence, Hamiyet Yilmaz, Ayfer Colak, Hulya Yalcin, Burak Toprak, Hakan Turkon, Levent Ugurlu, Cengiz Aydin
DOI: 10.5603/EP.a2016.0029
·
Endokrynologia Polska 2016;67(5):481-486.

open access

Vol 67, No 5 (2016)
Original papers
Published online: 2016-01-25
Submitted: 2015-09-08
Accepted: 2015-10-20

Abstract

Introduction: Irisin, a recently identified myokine, is associated with increased energy expenditure and has a potential role in obesity. Therefore, we investigated circulating irisin levels in morbidly obese patients undergoing sleeve gastrectomy (SG).

Material and methods: Thirty morbidly obese patients undergoing SG and 30 healthy subjects were included. All participants were evaluated at baseline and again at three months post-SG. Body weight and height, the lipid profile, and plasma glucose, HbA1c, insulin, and irisin levels were measured at each visit.

Results: The two groups had similar mean age and sex distribution. Serum irisin was significantly lower in the morbidly obese subjects compared with the controls (p = 0.003) and negatively correlated with BMI, body weight, insulin levels, and HOMA-IR (p = 0.006, p = 0.011, p = 0.046, p = 0.048, respectively). When the morbidly obese patients were re-evaluated three months post-SG, their weight and BMI had significantly decreased (both p = 0.001). Similarly, the insulin, HbA1c, HDL-cholesterol, and HOMA-IR values significantly decreased (p = 0.001, p = 0.028, p = 0.006, and p = 0.001, respectively). However, irisin levels remained unchanged (p = 0,267).

Conclusion: Although the irisin levels were significantly lower in the morbidly obese subjects, they did not change after SG-induced weight loss. (Endokrynol Pol 2016; 67 (5): 481–486)

Abstract

Introduction: Irisin, a recently identified myokine, is associated with increased energy expenditure and has a potential role in obesity. Therefore, we investigated circulating irisin levels in morbidly obese patients undergoing sleeve gastrectomy (SG).

Material and methods: Thirty morbidly obese patients undergoing SG and 30 healthy subjects were included. All participants were evaluated at baseline and again at three months post-SG. Body weight and height, the lipid profile, and plasma glucose, HbA1c, insulin, and irisin levels were measured at each visit.

Results: The two groups had similar mean age and sex distribution. Serum irisin was significantly lower in the morbidly obese subjects compared with the controls (p = 0.003) and negatively correlated with BMI, body weight, insulin levels, and HOMA-IR (p = 0.006, p = 0.011, p = 0.046, p = 0.048, respectively). When the morbidly obese patients were re-evaluated three months post-SG, their weight and BMI had significantly decreased (both p = 0.001). Similarly, the insulin, HbA1c, HDL-cholesterol, and HOMA-IR values significantly decreased (p = 0.001, p = 0.028, p = 0.006, and p = 0.001, respectively). However, irisin levels remained unchanged (p = 0,267).

Conclusion: Although the irisin levels were significantly lower in the morbidly obese subjects, they did not change after SG-induced weight loss. (Endokrynol Pol 2016; 67 (5): 481–486)

Get Citation

Keywords

Irisin; obesity; bariatric surgery; sleeve gastrectomy; insulin

About this article
Title

The effect of sleeve gastrectomy on serum irisin levels in patients with morbid obesity

Journal

Endokrynologia Polska

Issue

Vol 67, No 5 (2016)

Pages

481-486

Published online

2016-01-25

DOI

10.5603/EP.a2016.0029

Bibliographic record

Endokrynologia Polska 2016;67(5):481-486.

Keywords

Irisin
obesity
bariatric surgery
sleeve gastrectomy
insulin

Authors

Mustafa Demirpence
Hamiyet Yilmaz
Ayfer Colak
Hulya Yalcin
Burak Toprak
Hakan Turkon
Levent Ugurlu
Cengiz Aydin

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl